Alyaa Al-Mughairy: Rethinking Emicizumab Low-Dose Regimens to Ensure Safe and Sustainable Patient Access
Alyaa Al-Mughairy, Pediatric Hematology Oncology Senior Consultant at Ministry of Health Oman,and National Oncology Centre at Royal Hospital, shared Michael Makris‘s post on LinkedIn, adding:
”While standard maintenance doses for Emicizumab in hemophilia A target high plasma concentrations, real-world clinical experience in low economic countries, including our own suggests a low-dose regimens can still effectively maintain a 0.0 Annual bleeding rate for spontaneous bleeds.
This suggests that for many, we may be dosing beyond what is strictly necessary for clinical efficacy based in the standard approved doses.
It’s time to re-consider low doses regimen, ensuring sustainable access driven model of care to all patients without compromising patient safety or posing burden on the healthcare system.”
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared a post on LinkedIn:
”The approved dose of Hemlibra (emicizumab) is generous, and smaller doses are likely to be effective.
You can read the arguments in my commentary published in the current issue of the Journal of Thrombosis and Haemostasis.”
Title: Is all the approved emicizumab dose essential?
Author: Michael Makris
Read the Full Article on JTH
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 29, 2026, 07:12Matteo Foschi: Is There a Benefit to Switching DOACs After Breakthrough Stroke?
-
Apr 29, 2026, 07:02Enrico Ferro: Stroke Risk in PFA vs Radiofrequency Ablation
-
Apr 29, 2026, 06:03Proud to Recognize 6 Early Career Investigators as the Recipients of the 2026 JTH Editors’ Awards – JTH
-
Apr 29, 2026, 05:55On Hemophilia Care Advances, Collaboration and Access in India at IHC X 2026 – Hemophilia Federation India
-
Apr 29, 2026, 05:46Rajendra Tapadia: Strengthening Last-Mile Hemophilia Care Through Structured Community Outreach
-
Apr 29, 2026, 05:37Masoabi Sefojane: Whose Realities Shape Global Priorities in Hemophilia Care?
-
Apr 29, 2026, 05:24Filippo Cademartiri: Mandatory Reading for Anyone Who Mistakes Expertise for Certainty
-
Apr 29, 2026, 02:52Fengqian Chen: Another Reality Check for the Factor XI Inhibitor Race – Novartis’ Abelacimab Setback
-
Apr 29, 2026, 02:18Arnaud Baldivia: Peri-Procedural Stroke – An Underestimated Emergency in the Operating Room and in the ICU